← Back to Search

Tyrosine Kinase Inhibitor

Volociximab + Erlotinib for Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by Jonsson Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Measurable disease

ECOG performance status 0-1

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying volociximab and erlotinib as a possible treatment for non-small cell lung cancer.

Who is the study for?

This trial is for adults with advanced non-small cell lung cancer (stage III or IV) who have either failed at least one chemotherapy treatment or refused first-line therapy. They must not be pregnant, should use effective contraception if fertile, and have adequate organ function as indicated by specific blood counts and chemistries.Check my eligibility

What is being tested?

The study is testing the combination of volociximab, a monoclonal antibody that may block tumor blood flow, with erlotinib, an enzyme inhibitor that could stop tumor growth. This phase II trial aims to see how well this combo works in treating patients with advanced lung cancer.See study design

What are the potential side effects?

Potential side effects include reactions related to the immune system's response to monoclonal antibodies like volociximab and issues from blocking enzymes with erlotinib such as rash or diarrhea. Specific side effects will depend on individual patient responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer can be measured by tests.

Select...

I am fully active or can carry out light work.

Select...

My lung cancer is at an advanced stage (IIIB or IV).

Select...

I do not have uncontrolled seizures or active brain diseases.

Select...

I haven't had a stroke or deep vein clot in the last year.

Select...

I have either not responded to at least one chemotherapy treatment or refused initial treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of patients with confirmed tumor response

Secondary outcome measures

Adverse events and serious adverse events

Duration of response

Immunogenicity

+2 more

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor

359 Previous Clinical Trials

26,075 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,153 Total Patients Enrolled

Robert A. Figlin, MD, FACPStudy ChairJonsson Comprehensive Cancer Center

6 Previous Clinical Trials

Media Library

Erlotinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00278187 — Phase 2

Lung Cancer Clinical Trial 2023: Erlotinib Highlights & Side Effects. Trial Name: NCT00278187 — Phase 2

Erlotinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00278187 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research project presently seeking participants?

"According to clinicaltrials.gov, this medical experiment has ceased actively recruiting patients and was last updated on December 18th 2013. Nonetheless, over two thousand other trials are still enrolling volunteers as of now."

Answered by AI

What risks come with this particular course of treatment?

"Though it has yet to be proven effective, there is evidence of safety in the form of Phase 2 trial data. Therefore, our team at Power assigned this treatment a score of 2 on their scale from 1-3."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

2005. "Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00278187.

All > Lung > Sclc